NOVEL DRUGS APPROACHES IN TYPE 2 DIABETES MELLITUS
Shivani S. Ingawale and Aryan Vakilchand Langeh*
ABSTRACT
Diabetes mellitus belongs to the most rapidly increasing diseases worldwide. Approximately 90–95% of these patients suffer from type 2 diabetes mellitus. Chronic hyperglycemia and other metabolic disturbances of diabetes mellitus lead to long term tissue and organ damage as well as dysfunctions involving the eye, kidneys, and nervous systems and vascular system. Type 2 diabetes mellitus (DM) is a disorder characterised by insulin resistance and a progressive decline in pancreatic beta-cell function associated with increasing hyperglycaemia. This review will briefly summarize novel type 2 anti-diabetic drugs. Their suitability as ‗ideal anti-diabetic drugs‘ will be discussed. Undesirable side-effects may hamper treatment in those treated with the older medications. There is a need for novel treatment options that can help overcome these difficulties. The aim of this article is to present an overview of all the available novel type 2 antidiabetic drugs according to the different classes, their mechanisms of action and pharmacological profiles, and to assist physicians to make the correct choice for their patients. This article is written about the need for novel drug delivery systems in the treatment of type 2.
Keywords: Type 2 diabetes mellitus, Qtern, Lixisenatide, Soliqua, Invokamet ,Xultophy. long term efficacy. SGLT2 inhibitors.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
